Physician profile
Susan Kim
NPI 1972986768
$2,171.06
in general payments reported to CMS, 2019-2025
29 companies · $470 in 2025
The $470 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $278 · 2020: $74.68 · 2021: $339 · 2022: $384 · 2023: $385 · 2024: $241 · 2025: $470.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,034 · Education: $61.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,033.89 |
| Education | $61.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $381.37 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $175.43 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $175.32 | 2019-2025 | |
| Glaxosmithkline, LLC. | $169.95 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Astellas Pharma US INC | $143.29 | 2019-2025 | Veozah |
| Amgen INC. | $129.68 | 2019-2021 | |
| Abbvie INC. | $98.35 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $92.68 | 2022-2023 | |
| Sanofi-Aventis U.S. LLC | $88.29 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $80.49 | 2019-2023 | Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $67.13 | 2021-2023 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.31 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $57.14 | 2023-2025 | Gemtesa |
| Axsome Therapeutics, INC. | $49.41 | 2024-2025 | Auvelity |
| Merck Sharp & Dohme LLC | $47.99 | 2020-2025 | Lagevrio, Verquvo |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $44.83 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $44.43 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $34.13 | 2021 | |
| Inspire Medical Systems, INC. | $30.67 | 2025 | Inspire |
| Exact Sciences Corporation | $29.54 | 2024-2025 | Cologuard Collection Kit |
| Acadia Pharmaceuticals INC | $24.80 | 2025 | Daybue |
| Corcept Therapeutics | $24.62 | 2024 | Korlym |
| Janssen Pharmaceuticals, INC | $23.71 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $23.63 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.01 | 2023 | |
| Esperion Therapeutics, INC. | $17.14 | 2025 | Nexletol |
| Nevro Corp. | $14.62 | 2024 | Senza |
| Idorsia Pharmaceuticals US INC | $14.28 | 2024 | Quviviq |
| Amarin Pharma, INC. | $11.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.